Similar results were observed in fibrosarcoma xenografted mice, and the biological basis of the ASMase pathway in FUS-MB treatment was established since ASMase knockout mice and groups treated with sphingosine-1-phosphate (ASMase-ceramide pathway inhibitor) failed to demonstrate radioenhanced effects20. Here, SMPD1 is linked to fibrosarcoma.